In this application, the University of North Carolina at Chapel Hill (UNC) Divisions of Adult and Pediatric Hematology/Oncology, the Department of Radiation Oncology, the UNC Lineberger Comprehensive Cancer Center (LCCC) and the Division of Gastroenterology and Hepatology propose to renew funding for the UNC Oncology Clinical/ Translational Research Training Program (OCT-RTP). All four of the components will contribute mentors and research resources to the proposed training program, and all components except UNC-LCCC will contribute scholars. OCT-RTP will admit two scholars per year. The PI, Dr. Norman Sharpless, is Professor of Medicine and Genetics, a member of the Hematology/Oncology division, and is the LCCC Associate Director for Translational Research. Dr. Sharpless has extensive experience in cancer research in the areas of murine models, novel therapeutics, Phase I trials and commercialization of intellectual property. Dr Thomas Stinchcombe, Associate Professor and Hematology/Oncology fellowship program director, has newly assumed the role of Program Director. The program's objectives are to establish a highly motivated and rigorously trained cadre of physician clinical researchers who are competitive in seeking research support and who will become successful, independent patient-oriented cancer investigators. Training resources that will be available for the OCT-RTP include: the Lineberger Comprehensive Cancer Center, the North Carolina Cancer Hospital, the UNC School of Medicine K30 Clinical Research Curriculum and the UNC Program on Ethnicity Culture and Health Outcomes. The goals of the OCT-RTP are to increase the quality and quantity of patient-oriented research, including all phases of clinical research and particularly that involving a translational component. The foundation of the proposed training program will be the participation of highly qualified basic science and clinical mentors assigned to each scholar with mentoring activities coordinated by a mentor integration panel. An internal advisory committee that includes senior faculty from each of the four components will select and monitor the progress of scholars, while an external advisory committee will review the program annually. Since its inception, the OCT-RTP has enrolled six Scholars who records are detailed in the progress report. Our mentorship panel has evolved as some faculty members have left and new faculty have been recruited. One external advisory board member has rotated off and been replaced by A William Blackstock MD. Facilities and resources for the program have evolved to insure even stronger support for this program since its initial funding.

Public Health Relevance

The rapid pace of both laboratory and clinical discoveries in cancer research has created the need to develop a new generation of cancer researchers who are able to perform both clinical and laboratory research, often referred to as translational research. The development of this new cadre of highly motivated and rigorously trained physicians will accelerate the speed of advances in cancer care. The purpose of the K12 program at UNC is to assist in the development of these physicians through a program of required courses, research support, grant writing support, and close mentoring by senior faculty members. While in the K12 program scholars from the fields of radiation oncology, adult and pediatric oncology, gastroenterology and hepatology will collaborate with senior investigators at Lineberger Comprehensive Cancer Center on a research project. The ultimate goal of the program is to develop clinician scientists and research projects that will be independently funded, and physicians who will be able to mentor the next generation of physicians.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA120780-09
Application #
8921117
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
2006-07-01
Project End
2017-08-31
Budget Start
2015-09-01
Budget End
2016-08-31
Support Year
9
Fiscal Year
2015
Total Cost
$135,139
Indirect Cost
$41,813
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Williams, Grant R; Deal, Allison M; Sanoff, Hanna K et al. (2018) Frailty and health-related quality of life in older women with breast cancer. Support Care Cancer :
Bryant, Ashley Leak; Deal, Allison M; Battaglini, Claudio L et al. (2018) The Effects of Exercise on Patient-Reported Outcomes and Performance-Based Physical Function in Adults With Acute Leukemia Undergoing Induction Therapy: Exercise and Quality of Life in Acute Leukemia (EQUAL). Integr Cancer Ther 17:263-270
Molenaar, Remco J; Maciejewski, Jaroslaw P; Wilmink, Johanna W et al. (2018) Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene 37:1949-1960
Williams, Grant R; Deal, Allison M; Shachar, Shlomit Strulov et al. (2018) The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. Cancer Chemother Pharmacol 81:413-417
Lund, Jennifer L; Sanoff, Hanna K; Peacock Hinton, Sharon et al. (2018) Potential Medication-Related Problems in Older Breast, Colon, and Lung Cancer Patients in the United States. Cancer Epidemiol Biomarkers Prev 27:41-49
Bryant, Ashley Leak; Coffman, Erin M; Bullard, Elizabeth et al. (2018) Experiences of Inpatient Bone Marrow Transplantation Nurses and Providers Using Electronic Symptom Reporting. J Oncol Pract 14:e496-e504
Cuthbertson, Carmen C; Kucharska-Newton, Anna; Faurot, Keturah R et al. (2018) Controlling for Frailty in Pharmacoepidemiologic Studies of Older Adults: Validation of an Existing Medicare Claims-based Algorithm. Epidemiology 29:556-561
Williams, Grant R; Deal, Allison M; Muss, Hyman B et al. (2018) Frailty and skeletal muscle in older adults with cancer. J Geriatr Oncol 9:68-73
Saito, Ryoichi; Smith, Christof C; Utsumi, Takanobu et al. (2018) Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy. Cancer Res 78:3954-3968
Agle, Kimberle; Vincent, Benjamin G; Piper, Clint et al. (2018) Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD. Blood 132:435-447

Showing the most recent 10 out of 128 publications